Tango Therapeutics, Inc.
7
5
5
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
28.6%
2 terminated/withdrawn out of 7 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Role: lead
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Role: lead
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Role: lead
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Role: lead
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Role: collaborator
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Role: lead
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Role: lead
All 7 trials loaded